Disclaimer: This is an early beta prototype. If you find any error, with data or functionality, please let us know via this page.
OSP finalist
Open Knowledge
Advanced search
Action period

  1. Label

    Action date:
    FDA Application:
    NDA208054
    Drug:
    Axumin
    Active Ingredients:
    Fluciclovine f-18
    • ...HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AXUMIN safely and effectively. See full...
    • ...FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE Axumin is indicated for positron emission tomography (PET) in men with suspected prostate...

  2. Letter

    Action date:
    FDA Application:
    NDA208054
    Drug:
    Axumin
    Active Ingredients:
    Fluciclovine f-18
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 208054 NDA APPROVAL Michelle Wilson, Ph.D. U.S. Agent...
    • ...NDA 208054 Page 2 Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications (June 2008). Alternatively, you may...

  3. Summary Review

    Action date:
    FDA Application:
    NDA208054
    Drug:
    Axumin
    Active Ingredients:
    Fluciclovine f-18
    • ...CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 2080540rig15000 SUMMARY REVIEW...
    • ...Division Director Summary Review NDA 208054, Axumin (Fluciclovine 18) Libero Marzella MD, Division Director Summary Review for Regulatory Action...

  4. Label

    Action date:
    FDA Application:
    NDA208036
    Drug:
    E-z-hd
    Active Ingredients:
    Barium sulfate
    • ...HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use E-Z-HD safely and effectively. See full...
    • ...FULL PRESCRIBING INFORMATION: CONTENTS* 1 2 3 4 5 INDICATIONS AND USAGE DOSAGE AND ADMINISTRATION DOSAGE FORMS AND STRENGTHS CONTRAINDICATIONS...

  5. Letter

    Action date:
    FDA Application:
    NDA208036
    Drug:
    E-z-hd
    Active Ingredients:
    Barium sulfate
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 208036 NDA APPROVAL Bracco Diagnostics Inc. Attention...
    • ...NDA 208036 Page 2 CARTON AND IMMEDIATE CONTAINER LABELS Submit final printed carton and immediate container labels that are identical to the carton...

  6. Label

    Action date:
    FDA Application:
    NDA208032
    Drug:
    Kovanaze
    Active Ingredients:
    Oxymetazoline hydrochloride; tetracaine hydrochloride
    • ...HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use KOVANAZETM NASAL SPRAY safely and effectively...
    • ...FULL PRESCRIBING INFORMATION 1 INDICATIONS AND USAGE KOVANAZETM is indicated for regional anesthesia when performing a restorative procedure...

  7. Letter

    Action date:
    FDA Application:
    NDA208032
    Drug:
    Kovanaze
    Active Ingredients:
    Oxymetazoline hydrochloride; tetracaine hydrochloride
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 208032 NDA APPROVAL St. Renatus, LLC 1000 Centre Ave...
    • ...NDA 208032 Page 2 CARTON AND IMMEDIATE CONTAINER LABELS Submit final printed carton and immediate container labels that are identical to the enclosed...

  8. Letter

    Action date:
    FDA Application:
    NDA208030
    Drug:
    Ferriprox
    Active Ingredients:
    Deferiprone
    • ...DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration Silver Spring MD 20993 NDA 208030 ACCELERATED APPROVAL ApoPharma Inc. c/o Cato...
    • ...NDA 208030 Page 2 of labeling must be identical to the enclosed labeling (text for the package insert and Medication Guide). Information...

  9. Summary Review

    Action date:
    FDA Application:
    NDA208030
    Drug:
    Ferriprox
    Active Ingredients:
    Deferiprone
    • ...CENTER FOR DRUG EVALUATION AND RESEARCH APPLICATION NUMBER: 2080300rig15000 SUMMARY REVIEW...
    • ...Deputy Division Director Summary Review for Regulat01y Action...

  10. Label

    Action date:
    FDA Application:
    NDA208026
    Drug:
    Jentadueto xr
    Active Ingredients:
    Linagliptin; metformin hydrochloride
    • ...HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JENTADUETO XR safely and effectively. See full...
    • ..._______________________________________________________________________________________________________________________________________ FULL...